{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T14:48:01Z","timestamp":1786718881285,"version":"build-2736575974"},"reference-count":31,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Can Res Ther"],"published-print":{"date-parts":[[2020]]},"DOI":"10.4103\/jcrt.jcrt_983_17","type":"journal-article","created":{"date-parts":[[2019,2,5]],"date-time":"2019-02-05T06:02:55Z","timestamp":1549346575000},"page":"150","source":"Crossref","is-referenced-by-count":3,"title":["Investigating the cytotoxic and apoptotic effects of sunitinib upon K-562 chronic myelogenous leukemia cell line and assessment of gene profiling"],"prefix":"10.4103","volume":"16","author":[{"given":"MeldaComert","family":"Ozkan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"BurcinTezcanli","family":"Kaymaz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ajda","family":"Gunes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"BuketKosova","family":"Can","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"NurAkad","family":"Soyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"AsuFergun","family":"Yilmaz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Filiz","family":"Vural","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fahri","family":"Sahin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guray","family":"Saydam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"key-10.4103\/0973-1482.251626-1","first-page":"290","volume-title":"Letter: A new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining","author":"Rowley","year":"1973","journal-title":"Nature"},{"key":"key-10.4103\/0973-1482.251626-2","first-page":"3036","volume-title":"Targeted drugs in chronic myeloid leukemia","author":"Gora-Tybor","year":"2008","journal-title":"Curr Med Chem"},{"key":"key-10.4103\/0973-1482.251626-3","first-page":"3","volume-title":"Advances in the structural biology, design and clinical development of BCR-ABL kinase inhibitors for the treatment of chronic myeloid leukaemia","author":"Manley","year":"2005","journal-title":"Biochim Biophys Acta"},{"key":"key-10.4103\/0973-1482.251626-4","first-page":"10","volume-title":"Role of vascular endothelial growth factor in physiologic and pathologic angiogenesis: Therapeutic implications","author":"Ferrara","year":"2002","journal-title":"Semin Oncol"},{"key":"key-10.4103\/0973-1482.251626-5","first-page":"1761","volume-title":"Elevated plasma levels of vascular endothelial growth factor is associated with marked splenomegaly in chronic myeloid leukemia","author":"Liu","year":"2005","journal-title":"Leuk Lymphoma"},{"key":"key-10.4103\/0973-1482.251626-6","first-page":"3569","volume-title":"Expression of VEGF and its effect on cell proliferation in patients with chronic myeloid leukemia","author":"Chen","year":"2015","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"key-10.4103\/0973-1482.251626-7","first-page":"884","volume-title":"Sunitinib: From rational design to clinical efficacy","author":"Chow","year":"2007","journal-title":"J Clin Oncol"},{"key":"key-10.4103\/0973-1482.251626-8","first-page":"54","volume-title":"Drug-induced immune-mediated thrombocytopenia secondary to sunitinib in a patient with metastatic renal cell carcinoma: A case report","author":"Ansari","year":"2013","journal-title":"J Med Case Rep"},{"key":"key-10.4103\/0973-1482.251626-9","first-page":"1116","volume-title":"Discovery of 5-[5-fluoro-2-oxo-1,2- dihydroindol-(3Z)-ylidenemethyl]-2,4- dimethyl-1H-pyrrole-3-carboxylic acid (2-diethylaminoethyl) amide, a novel tyrosine kinase inhibitor targeting vascular endothelial and platelet-derived growth factor receptor tyrosine kinase","author":"Sun","year":"2003","journal-title":"J Med Chem"},{"key":"key-10.4103\/0973-1482.251626-10","first-page":"624","volume-title":"Tandem-duplicated flt3 constitutively activates STAT5 and MAP kinase and introduces autonomous cell growth in IL-3-dependent cell lines","author":"Hayakawa","year":"2000","journal-title":"Oncogene"},{"key":"key-10.4103\/0973-1482.251626-11","first-page":"3907","volume-title":"Flt3 mutations from patients with acute myeloid leukemia induce transformation of 32D cells mediated by the ras and STAT5 pathways","author":"Mizuki","year":"2000","journal-title":"Blood"},{"key":"key-10.4103\/0973-1482.251626-12","first-page":"2522","volume-title":"The antitumor effects of sunitinib (formerly SU11248) against a variety of human hematologic malignancies: Enhancement of growth inhibition via inhibition of mammalian target of rapamycin signaling","author":"Ikezoe","year":"2006","journal-title":"Mol Cancer Ther"},{"key":"key-10.4103\/0973-1482.251626-13","first-page":"301","volume-title":"Effector mechanisms of sunitinib-induced G1 cell cycle arrest, differentiation, and apoptosis in human acute myeloid leukaemia HL60 and KG-1 cells","author":"Teng","year":"2013","journal-title":"Ann Hematol"},{"key":"key-10.4103\/0973-1482.251626-14","first-page":"865","volume-title":"Blockade of MEK\/ERK signaling enhances sunitinib-induced growth inhibition and apoptosis of leukemia cells possessing activating mutations of the FLT3 gene","author":"Nishioka","year":"2008","journal-title":"Leuk Res"},{"key":"key-10.4103\/0973-1482.251626-15","first-page":"965","volume-title":"Effect of SU11248 on leukemia cell line K562 and its molecular mechanisms","author":"Luo","year":"2014","journal-title":"Zhongguo Shi Yan Xue Ye Xue Za Zhi"},{"key":"key-10.4103\/0973-1482.251626-16","first-page":"3597","volume-title":"SU11248 is a novel FLT3 tyrosine kinase inhibitor with potent activity in vitro and in vivo","author":"O'Farrell","year":"2003","journal-title":"Blood"},{"key":"key-10.4103\/0973-1482.251626-17","first-page":"5465","volume-title":"An innovative phase I clinical study demonstrates inhibition of FLT3 phosphorylation by SU11248 in acute myeloid leukemia patients","author":"O'Farrell","year":"2003","journal-title":"Clin Cancer Res"},{"key":"key-10.4103\/0973-1482.251626-18","first-page":"4009","volume-title":"SU11248 maintenance therapy prevents tumor regrowth after fractionated irradiation of murine tumor models","author":"Schueneman","year":"2003","journal-title":"Cancer Res"},{"key":"key-10.4103\/0973-1482.251626-19","first-page":"1011","volume-title":"Preclinical evaluation of the tyrosine kinase inhibitor SU11248 as a single agent and in combination with \u201cstandard of care\u201d therapeutic agents for the treatment of breast cancer","author":"Abrams","year":"2003","journal-title":"Mol Cancer Ther"},{"key":"key-10.4103\/0973-1482.251626-20","first-page":"327","volume-title":"In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: Determination of a pharmacokinetic\/pharmacodynamic relationship","author":"Mendel","year":"2003","journal-title":"Clin Cancer Res"},{"key":"key-10.4103\/0973-1482.251626-21","first-page":"694","volume-title":"Aphase I\/II study of sunitinib and intensive chemotherapy in patients over 60 years of age with acute myeloid leukaemia and activating FLT3 mutations","author":"Fiedler","year":"2015","journal-title":"Br J Haematol"},{"key":"key-10.4103\/0973-1482.251626-22","first-page":"S161","volume-title":"Investigating the role of JAK\/STAT pathway on dasatinib-induced apoptosis for CML cell model K562","author":"Dalg\u0131\u00e7","year":"2015","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"key-10.4103\/0973-1482.251626-23","first-page":"151","volume-title":"Repression of STAT3, STAT5A, and STAT5B expressions in chronic myelogenous leukemia cell line K-562 with unmodified or chemically modified siRNAs and induction of apoptosis","author":"Kaymaz","year":"2013","journal-title":"Ann Hematol"},{"key":"key-10.4103\/0973-1482.251626-24","first-page":"189","volume-title":"JAK\/STAT, raf\/MEK\/ERK, PI3K\/Akt and BCR-ABL in cell cycle progression and leukemogenesis","author":"Steelman","year":"2004","journal-title":"Leukemia"},{"key":"key-10.4103\/0973-1482.251626-25","first-page":"198","volume-title":"JAK2 as a molecular marker in myeloproliferative diseases","author":"Mata","year":"2007","journal-title":"Cardiovasc Hematol Agents Med Chem"},{"key":"key-10.4103\/0973-1482.251626-26","first-page":"458","volume-title":"Association of single nucleotide polymorphisms in STAT3, ABCB1, and ABCG2 with stomatitis in patients with metastatic renal cell carcinoma treated with sunitinib: A retrospective analysis in Japanese patients","author":"Watanabe","year":"2017","journal-title":"Biol Pharm Bull"},{"key":"key-10.4103\/0973-1482.251626-27","first-page":"2506","volume-title":"Sunitinib inhibition of stat3 induces renal cell carcinoma tumor cell apoptosis and reduces immunosuppressive cells","author":"Xin","year":"2009","journal-title":"Cancer Res"},{"key":"key-10.4103\/0973-1482.251626-28","first-page":"35","volume-title":"Sunitinib induces apoptosis and growth arrest of medulloblastoma tumor cells by inhibiting STAT3 and AKT signaling pathways","author":"Yang","year":"2010","journal-title":"Mol Cancer Res"},{"key":"key-10.4103\/0973-1482.251626-29","first-page":"2538","volume-title":"IL6-STAT3-HIF signaling and therapeutic response to the angiogenesis inhibitor sunitinib in ovarian clear cell cancer","author":"Anglesio","year":"2011","journal-title":"Clin Cancer Res"},{"key":"key-10.4103\/0973-1482.251626-30","first-page":"1893","volume-title":"Cdks and cyclins link G1 length and differentiation of embryonic, neural and hematopoietic stem cells","author":"Lange","year":"2010","journal-title":"Cell Cycle"},{"key":"key-10.4103\/0973-1482.251626-31","first-page":"2171","volume-title":"Sunitinib, an orally available receptor tyrosine kinase inhibitor, induces monocytic differentiation of acute myelogenous leukemia cells that is enhanced by 1,25-dihydroxyvitamin D(3)","author":"Nishioka","year":"2009","journal-title":"Leukemia"}],"container-title":["Journal of Cancer Research and Therapeutics"],"original-title":[],"language":"en","deposited":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T13:40:58Z","timestamp":1786714858000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/jcrt.JCRT_983_17"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020]]},"references-count":31,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020]]}},"alternative-id":["251626"],"URL":"https:\/\/doi.org\/10.4103\/jcrt.jcrt_983_17","relation":{},"ISSN":["0973-1482"],"issn-type":[{"value":"0973-1482","type":"print"}],"subject":[],"published":{"date-parts":[[2020]]}}}